TESA Research collaborates with biopharma, diagnostic, and academic partners. We bring computational expertise, an adaptable platform, and a team that understands both the science and the implementation path.
We support active pharma and biotech trials by identifying biomarkers that separate responders from non-responders, dramatically improving the odds of a positive readout.
Many drugs fail on endpoints, due to incorrect patient population rather than safety concerns. We partner on discontinued assets to identify the patient subgroups with high response potential.
We work with partners to systematically uncover biomarkers that open new development paths in well-defined patient subgroups.
Our founding team built genomic-interpretation software used in hundreds of clinical labs worldwide. We know how to move from algorithm to action.
Our platform has been validated in multiple active collaborations with internationally recognized cancer researchers at Dana Farber Cancer Institute, University of Southampton, and early-stage BioPharma company.
Whether you're validating new drug targets, exploring patient cohorts, or enhancing clinical assay performance, our tools can help.